The combination of osimertinib with pemetrexed or cisplatin has been investigated in EGFR-mutant NSCLC preclinical models.96 Furthermore, preliminary results have shown that the addition of platinum-based chemotherapy to osimertinib therapy is well tolerated in EGFR-TKI pre-treated patients.97,98 A Phase 1 study of carboplatin/etoposide plus osimertinib in EGFR-mutated patients with concurrent RB1 and TP53 alterations—in order to prevent SCLC transformation—is currently ongoing (NCT03567642). Here, EGFR is linked to non-small cell lung carcinoma.